Psoriasis (cardiovascular risk, tests before systemic treatment)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Severe psoriasis: assess cardiovascular risk
Fasting laboratory tests
- Lipid profile
- Fasting plasma glucose
- HIV serology (if HIV status unknown)if needednon-French guidelineSevere or atypical psoriasis: NICE makes it an HIV indicator condition [2] and recommends, in this case, offering a test to anyone in whom the infection has not been diagnosed [3]. The page already provides for HIV serology in the tests before systemic treatment (next tab).
Before systemic treatment (at the dermatologist's request)
Fasting laboratory tests
- FBC
- AST
- ALT
- GGT
- Bilirubin
- Serum creatinine with eGFR
- Fasting plasma glucose
- Hepatitis B serology (HBsAg, anti-HBs, anti-HBc)
- Hepatitis C serology
- HIV serology
- Serum β-hCG (woman of childbearing potential)if neededWoman of childbearing potential: pregnancy test recommended before each of the systemic treatments; before acitretin, then every month during treatment and 1 and 2 months after stopping, pregnancy having to be avoided for 3 years after stopping [4].
- Lipid profile (before ciclosporin or acitretin)if neededCiclosporin or acitretin: cholesterol and triglycerides before treatment and then during treatment [4] (hyperlipidaemia, a known adverse effect of both drugs [4]).
- IGRA test (before biologic therapy)if neededBefore a biologic: tuberculin skin test or IGRA, and chest X-ray, depending on the drug [4]. Reimbursed only before anti-TNF or anti-JAK [5].
Also consider
- Anti-TNF or biologic therapy planned? For the tests before biologic therapy, see the page "Biologic or JAK inhibitor: tests before treatment and monitoring".
- Methotrexate planned? For the tests before treatment and monitoring, see the page "Treatment: methotrexate".
- Acitretin planned? For the tests and monitoring, see the page "Treatment: acitretin".
Do not order
Sources (9)
- La Revue du Praticien. Psoriasis. Publié le 15 septembre 2019.
- National Institute for Health and Care Excellence. Psoriasis: assessment and management. Clinical guideline CG153, octobre 2012 (mise à jour septembre 2017) ; chapitre Recommendations, section 1.2.3 « Identification of comorbidities ».
- National Institute for Health and Care Excellence (NICE). HIV testing: increasing uptake among people who may have undiagnosed HIV. NICE guideline NG60, publiée le 1er décembre 2016, mise à jour le 26 septembre 2025 (recommandation 1.1.8).
- Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464-483.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 4103 (IGRA).
- Nast A, et al. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situations. J Dtsch Dermatol Ges. 2026;24(2):270-82.
- Nast A, Altenburg A, Augustin M, Bachmann F, Boehncke WH, Cornberg M, et al. S3 Guideline for the treatment of psoriasis vulgaris, adapted from EuroGuiDerm - part 1: Treatment recommendations and monitoring. J Dtsch Dermatol Ges. 2026;24(1):122-137.
- U.S. Food and Drug Administration. BIMZELX (bimekizumab), UCB : prescribing information (étiquetage américain), version du 16 juin 2025, rubrique « Warnings and precautions ».
- U.S. Food and Drug Administration. SOTYKTU (deucravacitinib), Bristol-Myers Squibb : prescribing information (étiquetage américain), version du 30 juin 2026, rubrique « Warnings and precautions ».